DUBLIN--(BUSINESS WIRE)--The "Sepsis Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
The major factors for the growth of the sepsis diagnostics market include the increasing prevalence of sepsis, the growing incidence of hospital-acquired infections, increasing number of pneumonia cases, rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities.
Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients, with an estimated incidence of 4.5 HAIs per 100 hospital admissions and an annual cost ranging between USD 35 billion and USD 45 billion. These HAIs are also called nosocomial infection.
According to the Centers for Disease Control and Prevention (CDC), about one in every 20 patients, who are admitted for the treatment, may develop a nosocomial infection. Hospital-acquired infections result in more than 99,000 deaths each year. HAIs are ranked among the top five leading causes of death in the United States. Some of the most common hospital-acquired infection cases include surgical infections, respiratory infections, urinary tract infections, and bloodstream infections.
Post-surgery bloodstream infections have increased by 8%, while urinary tract infections, due to the use of a catheter after surgery, have increased by 3.6%, as per the American Hospital Association. Healthcare facilities, care teams, and individual doctors and nurses are also aware of infection-related issues and take specific steps to prevent them.
Similar status of hospital-acquired infections has been observed across the world and is boosting the need for sepsis diagnosis. Hence, the rise in hospital-acquired infections is expected to drive the overall growth of the sepsis diagnosis market over the forecast period.
Key Market Trends
Molecular Diagnostics Segment under Technology-wise Segmentation is expected to be the Fastest Growing Segment over the Forecast Period
Sepsis, affecting nearly 1 out of every 23 hospitalized patients, is the sixth-most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Finally, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment.
These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis diagnostics. Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods.
The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method. However, the cost of molecular diagnostics has remained very high, as compared to conventional procedures, which restricts its market growth.
Several companies are investing in point of care molecular diagnostics for early diagnosis of bacterial and viral pathogens and better patient management. The well-established healthcare infrastructure with high adoption of advanced diagnostic technologies and raising awareness for early disease diagnosis is expected to drive the growth of the market studied.
North America is expected to hold the Largest Market Share in the Global Market
North America is found to hold a major share for the sepsis diagnostics market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the CDC statistics in 2018, sepsis affects more than a million Americans every year and leads to 15% to 30% deaths in the United States.
Furthermore, the number of cases of sepsis is rising on a yearly basis in the country, due to factors, such as the rise in geriatric population, infections that are incurable by antibiotics, and higher risks of the disease among people who have undergone an organ transplant. The National Institutes of Health supports many studies that are focused on sepsis, which is evaluating various potential treatments for the disease.
CDC launched 'Get Ahead of Sepsis', which is an educational initiative to protect Americans from the effect of sepsis. This initiative calls on healthcare professionals to educate patients, prevent infections, identify and diagnose sepsis at an early stage, and start sepsis treatment fast.
Emerging technologies linked with an enhanced understanding of the immature and developing neonatal immune system responses to early infection provide an opportunity to develop critically needed biomarkers to improve early identification in this high-risk population. So, the increasing prevalence of sepsis, along with government initiative may augment the growth of the market studied.
The market studied is moderately consolidated owing to the presence of a few key players. Some of the market players are Abbott, Becton, Dickinson, and Company, bioMerieux SA, Bruker Corporation, F. Hoffmann-LA Roche Ltd, Immunexpress Inc., Luminex Corporation, Response Biomedical Corp., T2 Biosystems, Inc., and Thermo Fisher Scientific.
Key Topics Covered
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Sepsis
4.2.2 Growing Incidence of Hospital-acquired Infections
4.2.3 Rise in the Number of Sepsis Procedures and Increase in Funding for Sepsis-related Research Activities
4.3 Market Restraints
4.3.1 High Cost of Automated Diagnostic Instruments
4.3.2 Lack of Well-established Reimbursement Policies for Sepsis
4.4 Porter's Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Molecular Diagnostics
5.1.4 Other Technologies
5.2 By Product
5.2.2 Assays and Reagents
5.2.3 Other Products
5.3 By Diagnostic Method
5.3.1 Conventional Diagnostics
5.3.2 Automated Diagnostics
5.4 By Pathogen
5.4.1 Bacterial Sepsis
5.4.2 Fungal Sepsis
5.4.3 Other Pathogens
5.5.1 North America
5.5.4 Middle East & Africa
5.5.5 South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.2 Becton, Dickinson, and Company
6.1.3 bioMerieux S.A.
6.1.4 Bruker Corporation
6.1.5 F. Hoffmann-LA Roche Ltd.
6.1.6 Immunexpress Inc.
6.1.7 Luminex Corporation
6.1.8 Response Biomedical Corp.
6.1.9 T2 Biosystems Inc.
6.1.10 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/ng3vna